Prime Medicine PRME Share-Based Payment Award Options Outstanding - Number
Share-Based Payment Award Options Outstanding - Number at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.
The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Prime Medicine's share-based payment award options outstanding - number.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Prime Medicine's share-based payment award options outstanding - number?
- Prime Medicine (PRME) reported share-based payment award options outstanding - number of 20.9M in Q1 2026.
- How has Prime Medicine's share-based payment award options outstanding - number changed year-over-year?
- Prime Medicine's share-based payment award options outstanding - number increased by 36.2% year-over-year, from 15.3M to 20.9M.
- What is the long-term trend for Prime Medicine's share-based payment award options outstanding - number?
- Over 4 years (2021 to 2025), Prime Medicine's share-based payment award options outstanding - number has grown at a 51.1% compound annual growth rate (CAGR), from 3M to 15.6M.
- What does share-based payment award options outstanding - number mean?
- This is the total count of stock options granted to employees and directors that remain unexercised at the reporting date. It reflects the total volume of potential equity claims currently held by the workforce. This metric is a key component in calculating fully diluted share counts.